Skip to content
NeuroTechGuide

China approves Neuracle's NEO, the world's first invasive BCI cleared for commercial use

The NMPA granted Class III approval for the implant, which restores basic hand grasp for people with cervical spinal cord injury.

1 min readRegulationImplants

China’s National Medical Products Administration (NMPA) has granted Class III marketing approval to NEO, a brain-computer interface from Shanghai-based Neuracle Medical Technology. It is described as the first invasive BCI cleared for commercial use anywhere in the world.

The device

NEO is meant for people with quadriplegia from cervical spinal cord injury (C2–C6). Coin-sized implants sit in the skull with electrodes resting outside the dura, the membrane covering the brain, so they don’t penetrate brain tissue. It is powered and read wirelessly. When the user attempts to move their hand, NEO decodes the signal and drives a pneumatic glove that restores a basic grasp.

The approval rests on a 36-participant multicenter trial. According to reports, all participants improved their grasping ability. Hospital leaders cautioned that the technology isn’t an instant fix and requires extensive training and rehabilitation.

Why it matters

US companies lead on electrode count and decoding performance, but no implanted BCI has yet reached market approval there; Synchron’s pivotal trial is still being prepared. China’s regulator moved first, with a deliberately simple, single-function device. The first commercial implant followed in July (our coverage), along with early pricing and insurance arrangements, an early test of how BCIs become routine care.

Learn more: ECoG · Invasive vs. non-invasive BCIs · Clinical trial pathway

Share:XLinkedInBlueskyEmail

More news